Search

Full-text search across all signals and tags

2 results for "weight-loss"

MarketsFeatured

8.4

Lilly launches Foundayo oral GLP-1 competing with Novo Nordisk's Wegovy

Eli Lilly has introduced Foundayo, a once-daily oral GLP-1 receptor agonist for weight loss, entering the competitive pharmaceutical market dominated by Novo Nordisk's Wegovy injection. The pill formulation addresses patient preference for oral administration over injections, potentially reshaping the weight-loss drug market. Market implications include competitive pricing pressure and expanded addressable patient population.

MarketWatch·US·about 5 hours ago

Confirmed

#pharmaceuticals #weight-loss #glp-1 #competitive-dynamics #healthcare-markets

MarketsFeatured

8.8

Eli Lilly receives FDA approval for oral weight-loss drug Foundayo

Eli Lilly has obtained US regulatory approval for Foundayo, an oral formulation targeting obesity, intensifying competition with Novo Nordisk's existing pill-based obesity treatments. This approval expands the competitive landscape in the high-growth obesity pharmaceutical market. Market implications include potential pricing pressure and market share redistribution among major pharmaceutical players.

Financial Times·US·about 4 hours ago

Confirmed

#pharma #obesity-treatment #market-competition #fda-approval #pharmaceutical-innovation